Chinese Ebola human vaccine declared safe and effective

China's early trial of an Ebola vaccine studied and developed by Chinese scientists has proven its safety, according to a paper published on The Lancet, one of the world's leading medical journals.

The findings suggest the high-dose vaccine is safe and "robustly immunogenic," its developers said Wednesday in the journal, adding that one shot of the high-dose vaccine could mount a "glycoprotein-specific humoral and T-cell response" against the Ebola virus in 14 days.

While early vaccines were based on a virus strain from 1976, the study marked the first Ebola vaccine that matched the 2014 West African Ebola virus.

The vaccine was jointly developed by the biotechnology institute of the Academy of Military Medical Sciences and Tianjin CanSino Biotechnology.

The team conducted the trial on 120 healthy Chinese volunteers who were randomly assigned a placebo, low dose or high dose of the vaccine.

According to the study, the new trial vaccine is stable and much easier to store or transport in tropical areas with inadequate cold-chain capacity, such as West Africa.

The outbreak of Ebola virus has been ongoing for about 16 months in West Africa.

More than 9,500 people across the three hardest-hit West African countries - Sierra Leone, Guinea and Liberia - have died from the disease.